Adventrx resubmits NSCLC candidate to FDA

Adventrx Pharmaceuticals Inc. (NYSE-A: ANX) resubmitted an NDA to FDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC). Adventrx said the submission included 12...